<b>Lower Limb Multilevel Treatment With Drug-Eluting Balloons:</b>6-Month Results From the DEBELLUM Randomized Trial

Abstract

The DEBELLUM trial confirmed the ability of paclitaxel-eluting balloons to reduce restenosis vs. conventional balloons at 6 months after treatment of multilevel (femoropopliteal and BTK) arterial disease in patients affected by claudication and CLI. A lower TLR rate and better clinical outcomes appear to be associated with the use of DEBs regardless of stent placement.